MAPK1 and myasthenia gravis: The results of molecular docking indicated that the major active compounds of SS had a strong binding activity with the hub targets, suggesting that isobrucine, vomicine, (s)-stylopine, strychnine, brucine-N-oxide, and brucine may play an anti-MG role by directly binding to AKT1, MAPK1, MAPK14, CHRM1, ACHE, and CHRNA4.